/
PHIO
$0.99+$0.02 (+1.55%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$11.3M
12M shares
52-week range
$0.81 – $4.19
5% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
29.58%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-240.93
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $138.0K | $21.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $4.3M | $0 | $3.7M | $8.9M | $7.0M | $6.3M | $3.6M | $0 |
| Gross profit | −$4.2M | $21.0K | −$3.7M | −$8.9M | −$7.0M | −$6.3M | −$3.6M | $0 |
| Gross margin | -3034.8% | 100.0% | — | — | — | — | — | — |
| R&D | $4.3M | $4.3M | $3.7M | $8.9M | $7.0M | $6.3M | $3.6M | $4.6M |
| Operating income | −$7.4M | −$9.0M | −$8.8M | −$13.5M | −$11.5M | −$10.8M | −$7.4M | −$9.2M |
| EBITDA | −$7.3M | −$8.9M | −$8.7M | −$13.2M | −$11.4M | −$10.6M | −$7.1M | −$8.7M |
| Net income | −$7.4M | −$8.9M | −$8.8M | −$13.3M | −$11.5M | −$10.8M | −$7.2M | −$8.7M |
| Net margin | -5333.3% | -42419.0% | — | — | — | — | — | — |
| EPS (diluted) | -6218.35 | -2074.18 | -207.25 | -111.32 | -89.61 | -46.76 | -0.91 | -1.45 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-1.38 | $-1.39–$-1.35 | 2 |
| 2027 | $0 | $-0.86 | $-1.02–$-0.70 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$3.45
Price
$0.98
Implied upside
+250%
Peer comparison
Phio Pharmaceuticals Corp. Common Stock
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
www.phiopharma.com- Employees
- 6
- IPO / List date
- May 10, 2012
- HQ
- KING OF PRUSSIA, PA
Held by traders on TradeandTell
No one on the platform currently holds PHIO.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in PHIO as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-07-05 | 1-for-9reverse |
| 2023-01-26 | 1-for-12reverse |
| 2020-01-15 | 1-for-55reverse |
| 2018-01-08 | 1-for-10reverse |
| 2016-04-18 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded PHIO yet.
